| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: =98.70%
Methylprednisolone sodium succinate (U-9088; 6α-Methylprednisolone 21-hemisuccinate sodium) is a water-soluble ester of Methylprednisolone (also known as NSC-19987) which is a synthetic and potent glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. It is used for cardiac, allergic, and hypoxic emergencies. Methylprednisolone sodium succinate has slightly longer half-life than that of Prednisolone.
| References |
|
|---|---|
| Additional Infomation |
Methylprednisolone sodium succinate is a corticosteroid hormone.
Methylprednisolone Sodium Succinate is the sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved. A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies. See also: Methylprednisolone (has active moiety). |
| Molecular Formula |
C26H33NAO8
|
|---|---|
| Molecular Weight |
496.53
|
| Exact Mass |
496.207
|
| Elemental Analysis |
C, 62.89; H, 6.70; Na, 4.63; O, 25.78
|
| CAS # |
2375-03-3
|
| Related CAS # |
Methylprednisolone succinate;2921-57-5
|
| PubChem CID |
23680530
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
689.6ºC at 760mmHg
|
| Flash Point |
230.7ºC
|
| LogP |
0.884
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
988
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@@]12[C@](C(COC(CCC([O-])=O)=O)=O)(O)CC[C@@]1([H])[C@]3([H])C[C@H](C)C4=CC(C=C[C@]4(C)[C@@]3([H])[C@@H](O)C2)=O.[Na+]
|
| InChi Key |
FQISKWAFAHGMGT-SGJOWKDISA-M
|
| InChi Code |
InChI=1S/C26H34O8.Na/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/q+1/p-1/t14-,16-,17-,19-,23+,24-,25-,26-/m0./s1
|
| Chemical Name |
Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-6-alpha-methyl-, 21- (hydrogen succinate), monosodium salt
|
| Synonyms |
Methylprednisolone sodium succinate; U 9088; U-9088; U9088
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL ~(100.70 mM)
Ethanol : ~100 mg/mL DMSO :25~100 mg/mL (50.35~201.39 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.08 mg/mL (4.19 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0140 mL | 10.0699 mL | 20.1398 mL | |
| 5 mM | 0.4028 mL | 2.0140 mL | 4.0280 mL | |
| 10 mM | 0.2014 mL | 1.0070 mL | 2.0140 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02425813 | Withdrawn | Drug: Budesonide Drug: Methylprednisolone Sodium Succinate |
Acute Graft Versus Host Disease Intestinal Graft Versus Host Disease |
Wake Forest University Health Sciences | 2015-10 | Phase 2 |
| NCT05649878 | Completed | Drug: Evaluation of bioavailability of methylprednisolone succinate administered intravenously Drug: Evaluation of bioavailability of methylprednisolone succinate administered intranasally |
Healthy Subjects Intranasal Administration Intravenous Administration Methylprednisone Administration |
Edda Sciutto Conde | 2021-11-05 | Not Applicable |
| NCT01167946 | Completed | Drug: methylprednisolone sodium succinate Drug: methylprednisolone sodium succinate Drug: methylprednisolone sodium succinate |
Alopecia Totalis Alopecia Universalis Ophiasic Alopecia |
King Saud University | 2003-01 | Phase 4 |
| NCT06360458 | Recruiting | Drug: Methylprednisolone sodium succinate Drug: Placebo (Methylprednisolone sodium succinate simulant) |
Acute Ischemic Stroke | Wan-Jin Chen | 2024-08-01 | Phase 3 |
| NCT04343729 | Completed | Drug: Methylprednisolone Sodium Succinate Drug: Placebo solution |
SARS-CoV Infection Severe Acute Respiratory Syndrome (SARS) Pneumonia |
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado |
2020-04-18 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA